


## Trimethoprim hydrochloride

|                           |   |
|---------------------------|---|
| <b>Cat. No.:</b>          | HY-B0510B   |
| <b>CAS No.:</b>           | 60834-30-2  |
| <b>Molecular Formula:</b> | C <sub>14</sub> H <sub>19</sub> ClN <sub>4</sub> O <sub>3</sub>                           |
| <b>Molecular Weight:</b>  | 326.78  |
| <b>Target:</b>            | Antibiotic; Bacterial; Antifolate; Influenza Virus  |
| <b>Pathway:</b>           | Anti-infection; Cell Cycle/DNA Damage   |
| <b>Storage:</b>           | Please store the product under the recommended conditions in the Certificate of Analysis. |



### BIOLOGICAL ACTIVITY

|                                     |   |               |   |         |          |                 |                                |         |  |
|-------------------------------------|---|---------------|---|---------|----------|-----------------|--------------------------------|---------|--|
| <b>Description</b>                  | <p>Trimethoprim hydrochloride is a bacteriostatic antibiotic and an orally active dihydrofolate reductase inhibitor. Trimethoprim hydrochloride is active against a wide range of Gram-positive and Gram-negative aerobic bacteria. Trimethoprim hydrochloride has the potential for the research of urinary tract infections, Shigellosis and Pneumocystis pneumonia. Trimethoprim hydrochloride can inhibit infection of Influenza A virus in chick embryo when combined with zinc<sup>[1][2][3][4]</sup>.</p>  |               |   |         |          |                 |                                |         |  |
| <b>IC<sub>50</sub> &amp; Target</b> | <p>Dihydrofolate reductase, Bacteria<sup>[1]</sup><br/>Influenza A virus<sup>[4]</sup></p>  |               |   |         |          |                 |                                |         |  |
| <b>In Vitro</b>                     | <p>Trimethoprim interrupts folate metabolism by inhibition of the activity of dihydrofolase reductase (DHFR), which reduces dihydrofolate to tetrahydrofolate (THF)<sup>[1]</sup>.</p> <p>Trimethoprim (3 µg/mL; 1 h) induces protein aggregation and main heat shock proteins (Hsps) in E. coli cells, which indicates that Trimethoprim sulfate presence leads to protein misfolding<sup>[1]</sup>.</p> <p>Trimethoprim (1.5-3 µg/mL; 1 h) causes induction of DnaK, DnaJ, GroEL, ClpB, and IbpA/B Hsps in E. coli cells exposed to folate and heat stress<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>  |               |   |         |          |                 |                                |         |  |
| <b>In Vivo</b>                      | <p>Trimethoprim (10 mg/kg; i.v.; once every 12 h; 3 d) shows antibacterial activity against H. influenzae, S. pneumoniae, E. coli and N. meningitidis in infected mice<sup>[2]</sup>.</p> <p>Trimethoprim can be connected with the thiomaltose (TM-TMP) and shows stability with a half-life of about 1 hour in complete serum, and has an MIC value around 1 µM against E. coli<sup>[2]</sup>.</p> <p>Trimethoprim (10 mg/mL; 0.5 mL; inject with Trimethoprim-Zn combined suspension) decreases the virus titer and increases the survival rate of chicken embryo<sup>[4]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Animal Model:</td> <td>Female C3H/HeOuJ mice (transurethrally infected with a 50 µL suspension containing 1-2×10<sup>7</sup> CFU of E. coli under 3% isoflurane)<sup>[2]</sup></td> </tr> <tr> <td>Dosage:</td> <td>10 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>i.v.; once every 12 h; for 3 d</td> </tr> <tr> <td>Result:</td> <td>Showed antibacterial activity against H. influenzae, S. pneumoniae, E. coli and N.</td> </tr> </table> | Animal Model: | Female C3H/HeOuJ mice (transurethrally infected with a 50 µL suspension containing 1-2×10 <sup>7</sup> CFU of E. coli under 3% isoflurane) <sup>[2]</sup> | Dosage: | 10 mg/kg | Administration: | i.v.; once every 12 h; for 3 d | Result: | Showed antibacterial activity against H. influenzae, S. pneumoniae, E. coli and N. |
| Animal Model:                       | Female C3H/HeOuJ mice (transurethrally infected with a 50 µL suspension containing 1-2×10 <sup>7</sup> CFU of E. coli under 3% isoflurane) <sup>[2]</sup>   |               |   |         |          |                 |                                |         |  |
| Dosage:                             | 10 mg/kg  |               |   |         |          |                 |                                |         |  |
| Administration:                     | i.v.; once every 12 h; for 3 d  |               |   |         |          |                 |                                |         |  |
| Result:                             | Showed antibacterial activity against H. influenzae, S. pneumoniae, E. coli and N.  |               |   |         |          |                 |                                |         |  |

meningitidis with CD<sub>50</sub>s of 150 mg/kg, 335 mg/kg, 27.5 mg/kg and 8.4 mg/kg, respectively in infected mice.

|                 |   |
|-----------------|---|
| Animal Model:   | Fertilized eggs (injected H3N2 virus into amniotic and allantoic space at day 8) <sup>[4]</sup>   |
| Dosage:         | 10 mg/mL; 0.5 mL  |
| Administration: | The Trimethoprim-Zn combined suspension was injected into the air sac; single dosage  |
| Result:         | Decreased the virus titer and increased the survival rate of chicken embryo.<br>The survival rate peaked at ratio about 0.18 (Zn/Trimethoprim). |

## CUSTOMER VALIDATION

- J Clin Microbiol. 2020 Jan 28;58(2):e01603-19.
- Chemosphere. 2019 Jun;225:378-387.
- J Mol Med (Berl). 2019 Aug;97(8):1183-1193.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

- [1]. Laskowska, E., et al., Trimethoprim induces heat shock proteins and protein aggregation in E. coli cells. Curr Microbiol, 2003. 47(4): p. 286-9.
- [2]. Brogden, R.N., et al., Trimethoprim: a review of its antibacterial activity, pharmacokinetics and therapeutic use in urinary tract infections. Drugs, 1982. 23(6): p. 405-30.
- [3]. Xiaojian Wang, et al. A Trimethoprim Conjugate of Thiomaltose Has Enhanced Antibacterial Efficacy In Vivo. Bioconj Chem. 2018 May 16;29(5):1729-1735.
- [4]. El Habbal MH. Combination therapy of zinc and trimethoprim inhibits infection of influenza A virus in chick embryo. Virol J. 2021 Jun 3;18(1):113.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA